Dr. Miller discusses new options for negative symptoms, how to improve the therapeutic alliance, and what to do when clozapine doesn’t work in schizophrenia.

In December 2021, the FDA approved lumateperone (Caplyta) for bipolar I and II depression, and here we report on one of the trials that led to that approval.

With so few pharmacologic options for methamphetamine use disorder, a large trial from The New England Journal of Medicine suggest bupropion and naltrexone are worth exploring.

Sleepwalking is a rare side effect on psychiatric medications, particularly hypnotics and antidepressants. A new analysis explores whether lithium and the antipsychotics should be added to that list.

What medications are best picks for treating agitation in children and adolescents in the emergency department setting? While there is little definitive research on the topic we looked at a retrospective study comparing quetiapine with first line antipsychotics that gives us a start at pulling the threads on this knotty problem.